Pterygium Clinical Trial
— SURPHOfficial title:
A Multicenter, Prospective, Randomized, Double-Masked, Phase 2 Study Evaluating the Safety, Tolerability, and Efficacy of Topical AG-86893 in Patients With Pterygium
Verified date | January 2020 |
Source | Allgenesis Biotherapeutics Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A pterygium is a wing-shaped, benign tissue growth which forms on the surface of the conjunctiva and grows towards the cornea. It can eventually lead to vision impairment. The precise cause of pterygium formation is unknown but new blood vessel growth and fibroblastic structures are characteristics of the disease. AG-86893 is an eye drop being developed to treat hyperemia (redness) and growth of the pterygium. Hypothesis 1. AG-86893 dosed three times daily for 28 consecutive days has an acceptable safety profile as measured by the incidence and severity of adverse events (AEs) compared with vehicle 2. At least 1 concentration of AG-86893 is effective, as measured by the mean change from baseline in conjunctival hyperemia (redness), compared with vehicle
Status | Completed |
Enrollment | 64 |
Est. completion date | October 25, 2019 |
Est. primary completion date | September 5, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Good health with no clinically significant findings based on the medical history, electrocardiogram, vital signs, blood chemistry, hematology, and urinalysis findings, as determined by the investigator - Females of childbearing potential must have a negative pregnancy test at baseline and must be on established, adequate contraception and males must use condoms if their partner is of childbearing potential and their female partner should also use an additional effective means of contraception, or they must agree to abstain from sexual intercourse with a female partner for the duration of the study; contraception should be continued for 3 months after the last dose. - Presence of pterygium with associated conjunctival hyperemia (redness) of grade =2 as assessed by a central reading center. Exclusion Criteria: - History or presence of any ocular diseases other than pterygium or its sequelae (after-effects), including neoplasia (uncontrolled overgrowth) - Diagnosis of ocular hypertension or glaucoma requiring use of intraocular pressure-lowering medication - Use of contact lenses during the study in the study eye - History or evidence of ocular surgeries in the study eye at any time - History of liver dysfunction or current abnormal liver enzymes - Pregnancy, plans for pregnancy, or breastfeeding during the study |
Country | Name | City | State |
---|---|---|---|
Australia | Bendigo Eye Clinic | Bendigo | Victoria |
Australia | Essendon Eye Clinic | Essendon | Victoria |
Australia | Lions Eye Institute | Nedlands | Western Australia |
Australia | M.T. Coroneo Pty Ltd | Randwick | New South Wales |
Australia | H2Vision Centre | Sippy Downs | Queensland |
Australia | The Geelong Eye Centre | Waurn Ponds | Victoria |
Lead Sponsor | Collaborator |
---|---|
Allgenesis Biotherapeutics Inc. |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change From Baseline in Overall Conjunctival Hyperemia Score | Assessed by digital ocular photography; each quadrant of the eye (superior, inferior, nasal, temporal) will be scored using a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe) and graded by a reading center. The overall conjunctival score is the average of the four quadrants. Assessments are made by subtracting the score at Baseline from the score on Day 28. An increase in value indicates worsening of hyperemia, while a decrease indicates improvement. | Baseline and Day 28 | |
Secondary | Change From Baseline in Conjunctival Hyperemia Score in the Quadrant With the Pterygium | Assessed by digital ocular photography; the quadrant with the pterygium will be scored using a 5-point scale (0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe) and graded by a reading center. Assessments are made by subtracting the score at Baseline from the score on Day 28. An increase in value indicates worsening of hyperemia, while a decrease indicates improvement. | Baseline and Day 28 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT02641132 -
Pterygium Head Body MMC1: Two Different Surgical Procedures and Their Effect on Endothelial Cell Count.
|
Phase 4 | |
Completed |
NCT02342392 -
Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study
|
Phase 2/Phase 3 | |
Recruiting |
NCT01387971 -
Using Impression Cytology to Observe the Cytological Changes of Ocular Surface Cells in Various Ocular Surface Disorders
|
N/A | |
Recruiting |
NCT05978687 -
The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision
|
Phase 4 | |
Not yet recruiting |
NCT06042296 -
Expression of CD44, PCNA and E-cadherin in Pterygium Tissue
|
||
Completed |
NCT04022811 -
Effect of Bromfenac on Pain Related to Pterygium Surgery
|
Phase 4 | |
Recruiting |
NCT01249235 -
Bandage Contact Lens and Oral Analgesics Versus Patching and Oral Analgesics for Pain Following Pterygium Surgery
|
N/A | |
Recruiting |
NCT01261455 -
Prospective Randomized Pilot Study Comparing Inferior Versus Superior Conjunctival Autografts for Primary Pterygia
|
N/A | |
Completed |
NCT01115517 -
Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery
|
Phase 2 | |
Completed |
NCT00768963 -
Ranibizumab for the Inhibition of Neovascularization in Pterygia
|
Phase 1 | |
Completed |
NCT00949728 -
Conjunctival Autologous Transplantation Using Fibrin Glue in Primary Pterygia
|
N/A | |
Recruiting |
NCT00563277 -
Surgical Treatment of Concurrent Cataract and Primary Pterygium
|
N/A | |
Completed |
NCT00346450 -
Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation
|
Phase 3 | |
Completed |
NCT04403516 -
Dextenza in Pterygium Surgery
|
Phase 4 | |
Recruiting |
NCT02911532 -
Tissue Engineering Conjunctiva for the Treatment of Pterygium and Atretoblepharia
|
N/A | |
Not yet recruiting |
NCT03304366 -
Corneal Changes With Pentacam Before and After Pterygium
|
N/A | |
Unknown status |
NCT02015000 -
Surgical Result of Pterygium Extended Removal Followed by Fibrin Glue Assisted Amniotic Membrane Transplantation
|
N/A | |
Completed |
NCT00344201 -
Assessment of Fibrin Glue in Pterygium Surgery and Other Forms of External Eye Surgery
|
Phase 1 | |
Recruiting |
NCT00326560 -
Comparison of Glue With Sutures for Pterygium Surgery
|
Phase 3 | |
Not yet recruiting |
NCT03314389 -
The Corneal and Conjunctiva Sensation Before and After Pterygium Surgeries
|
N/A |